Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
Cognitive impairment associated with schizophrenia predicts poor functional outcomes. Currently, no approved pharmacotherapy is available. This study investigated whether the glycine transporter-1 inhibitor BI 425809 improves cognition in patients with schizophrenia. Five of six dose–response models showed a statistically significant benefit over placebo.
